Table 9.
Pooled pain prevalence, and severity rates by treatment group.
| N Studies | N cancer Patients | Overall Pain | |
|---|---|---|---|
| Group 1 | 18 | 3294 | 40.3% (95% CI 30.2–50.4) |
| Group 2 | 31 | 7995 | 47.8% (95% CI 39.4–56.1) |
| Group 3 | 19 | 8719 | 54.3% (95% CI 42.0–66.6) |
| Group 4 | 32 | 9118 | 50.3% (95% CI 42.5–58.0) |
| Group 5 | 77 | 59,766 | 35.8% (95% CI 31.5–40.1) |
| Group 6 | 15 | 33,162 | 55.2% (95% CI 39.2–71.3) |
| Group 7 | 66 | 508,827 | 45.0% (95% CI 39.8–50.1) |
| Group 8 | 81 | 25,832 | 50.3% (95% CI 44.6–56.1) |
| Group 9 | 34 | 41,881 | 54.6% (95% CI 43.8–65.5) |
| Moderate–Severe Pain | |||
| Group 1 | 9 | 1895 | 33.1% (95% CI 22.0–44.2) |
| Group 2 | 12 | 5483 | 27.8% (95% CI 6.7–48.8) |
| Group 3 | 11 | 8057 | 39.1% (95% CI 30.0–48.1) |
| Group 4 | 16 | 4966 | 25.2% (95% CI 19.0–31.4) |
| Group 5 | 30 | 24,490 | 22.8% (95% CI 19.0–26.7) |
| Group 6 | 7 | 35,319 | 43.3% (95% CI 19.7–66.9) |
| Group 7 | 22 | 107,128 | 34.2% (95% CI 27.6–40.8) |
| Group 8 | 39 | 18,506 | 31.0% (95% CI 22.7–39.3) |
| Group 9 | 18 | 43,376 | 40.7% (95% CI 28.5–52.9) |
Group 1: treatment-naïve patients; Group 2: patients receiving curative treatment; Group 3: patients receiving palliative treatment; Group 4: patients receiving curative or palliative treatment, or treatment intent not specified; Group 5: after curative treatment; Group 6: patients without feasible anti-cancer treatment; Group 7: including patients in different phases of treatment; Group 8: patients on anti-cancer treatment; Group 9: patients with advanced, metastatic or terminal disease.